Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
SUMMARY: Endometrial cancer – the most common malignancy of the female reproductive tract – arises from the specialized epithelial cells that line the inner surface of the uterus. Although significant advances have been made in our understanding of this disease in recent years, one significant limitation has been the lack of a diverse genetic toolkit for the generation of mouse models. We identified a novel endometrial-specific gene, Sprr2f, and developed a Sprr2f-Cre transgene for conditional gene targeting within endometrial epithelium. We then used this tool to generate a completely penetrant Lkb1 (also known as Stk11)-based mouse model of invasive endometrial cancer. Strikingly, female mice with homozygous endometrial Lkb1 inactivation did not harbor discrete endometrial neoplasms, but instead underwent diffuse malignant transformation of their entire endometrium with rapid extrauterine spread and death, suggesting that Lkb1 inactivation was sufficient to promote the development of invasive endometrial cancer. Mice with heterozygous endometrial Lkb1 inactivation only rarely developed tumors, which were focal and arose with much longer latency, arguing against the idea – suggested by some prior studies – that Lkb1 is a haploinsufficient tumor suppressor. Lastly, the finding that endometrial cancer cell lines were especially sensitive to the mTOR (mammalian target of rapamycin) inhibitor rapamycin prompted us to test its efficacy against Lkb1-driven endometrial cancers. Rapamycin monotherapy not only greatly slowed disease progression, but also led to striking regression of pre-existing tumors. These studies demonstrate that Lkb1 is a uniquely potent endometrial tumor suppressor, but also suggest that the clinical responses of some types of invasive cancers to mTOR inhibitors may be linked to Lkb1 status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439 · cited 3×
“INTRODUCTION Endometrial cancer represents 6% of all cancer and is the most common cancer of the female reproductive tract, with 40,880 new cases and 7310 cancer-related deaths in 2005 in the USA alone (Jemal et al., 2007).”
BackgroundInfluentialThe LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943 · cited 3×
“…syndrome (PJS), an autosomal dominant condition characterized by hamartomatous polyps of the gastrointestinal (GI) tract (Alessi et al., 2006; Shackelford and Shaw, 2009) and a significantly elevated (>15 ) general risk of cancer including clinically and histopathologically distinctive…”
BackgroundBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447 · cited 2×
“Volumes were calculated with imaging processing software (ImageJ, version 1.40g; National Institutes of Health, Bethesda, MD), as described previously (Li et al., 2008).”
MethodSelf-citationLKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064
Self-citationGu, H., Zou, Y.-R., & Rajewsky, K. (1993) · Cell · doi:10.1016/0092-8674(93)90644-6 · Cited by 989 · cited 1×
“This Sprr2f promoter fragment was ligated to a cassette of the Cre recombinase open-reading frame (ORF) with an engineered nuclear localization sequence (CreN) (Gu et al., 1993).”
MethodJeong, J.-W., Lee, H. S., Franco, H. L., Broaddus, R. R., Taketo, M. M., Tsai, S. Y., Lydon, J. P., & DeMayo, F. J. (2009) · Oncogene · doi:10.1038/onc.2008.363 · Cited by 196
Cited by
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765
Physiological and molecular determinants of embryo implantation
Zhang, S., Lin, H., Kong, S., Wang, S., Wang, H., Wang, H., & Armant, D. R. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.12.011 · Cited by 587
Boretto, M., Maenhoudt, N., Luo, X., Hennes, A., Boeckx, B., Bui, B., Heremans, R., Perneel, L., Kobayashi, H., Van Zundert, I., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0360-z · Cited by 503
Boretto, M., Cox, B., Noben, M., Hendriks, N., Fassbender, A., Roose, H., Amant, F., Timmerman, D., Tomassetti, C., Vanhie, A., et al. (2017) · Development · doi:10.1242/dev.148478 · Cited by 459
“In addition, several markers of mouse endometrial epithelium (such as Cxcl15, Esr1, Foxa2,Muc1 and Sprr2f ) (Contreras et al., 2010; Jeong et al., 2010; Kelleher et al., 2017; Kobayashi and Behringer, 2003), which are present in the starting glandular fragments, were found to be expressed in the EMOs (Fig.”
BackgroundMonitoring Tumorigenesis and Senescence In Vivo with a p16INK4a-Luciferase Model
Burd, C. E., Sorrentino, J. A., Clark, K. S., Darr, D. B., Krishnamurthy, J., Deal, A. M., Bardeesy, N., Castrillon, D. H., Beach, D. H., & Sharpless, N. E. (2013) · Cell · doi:10.1016/j.cell.2012.12.010 · Cited by 419
Self-citation
Metadata
- Authors
- Contreras, C. M., Akbay, E. A., Gallardo, T. D., Haynie, J. M., Sharma, S., Tagao, O., Bardeesy, N., Takahashi, M., Settleman, J., Wong, K.-K., & Castrillon, D. H.
- Venue
- Disease Models & Mechanisms
- Publisher
- The Company of Biologists
- Published
- 2010-03-08
- Volume
- 3
- Issue
- 3-4
- Pages
- 181-193
- ISSN
- 1754-8403 (ISSN-L)
- 1754-8411
- OpenAlex
- W2143851306
- Cited by
- 125
- References
- 6
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. https://app.cochat.ai/papers/10.1242/dmm.004440
- The paper
- Contreras, C. M., Akbay, E. A., Gallardo, T. D., Haynie, J. M., Sharma, S., Tagao, O., Bardeesy, N., Takahashi, M., Settleman, J., Wong, K.-K., & Castrillon, D. H. (2010). Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy. Disease Models & Mechanisms. https://doi.org/10.1242/dmm.004440
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.